SCHEMBL5215733

SCHEMBL5215733

Oc1ccc(CCSc2ccc(Cl)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.47
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 1/20 0.46
GPR84 Q9NQS5 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
GFER P55789 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TEAD1 P28347 1/20 0.44
YAP1 P46937 1/20 0.44
TEAD4 Q15561 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28642267 1.00 IDO1 (0.47) IDO1ESR1ESR2NPC1RAB9A
SCHEMBL3234313 0.90 ESR1 (0.56) IDO1ESR1ESR2KMT2ACYP1A2
SCHEMBL10637449 0.90 ESR1 (0.56) IDO1ESR1ESR2KMT2ACYP1A2
SCHEMBL9813820 0.88 IGF1R (0.49) ESR1ESR2NPC1RAB9AGAA
SCHEMBL155779 0.82 MAOA (0.59) IDO1ESR1ESR2RAB9AKMT2A
SCHEMBL10719354 0.82 HDAC3 (0.51) NPC1RAB9AGAAMAPTKMT2A
SCHEMBL22894305 0.81 MEN1 (0.49) IDO1NPC1RAB9AMAPTKMT2A
SCHEMBL14492421 0.81 MEN1 (0.49) IDO1NPC1RAB9AMAPTKMT2A
SCHEMBL21331798 0.81 CYP1A2 (0.61) IDO1NPC1RAB9AKMT2AMAPK1
SCHEMBL7779170 0.81 MEN1 (0.67) IDO1NPC1RAB9AMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636213-B1 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY WARNER LAMBERT CO (US) 2007-06-13 EP disclosed
EP-1636213-A1 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY Warner-Lambert Company LLC (US) 2006-03-22 EP disclosed
US-20040259926-A1 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents BRUENDL MICHELLE M (US) 2004-12-23 US disclosed
WO-2004108715-A1 3-ARYLOXY AND 3-HETEROARYLOXY SUBSTITUTED BENZO(B) THIOPHENES AS THERAPEUTIC AGENTS WITH PI3K ACTIVITY WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259926-A1 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents MALT1, CYP1B1, CYP4B1 IDO1 887/4885ESR1 911/4885ESR2 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.